The rise in the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) for weight loss has generated significant interest due to their efficacy in reducing body weight. However, this trend has also highlighted a critical health concern: the unintended loss of muscle mass. While these therapies effectively shed excess pounds, they also contribute to a decrease in muscle mass, raising concerns about the potential long-term impact on overall health. This is of particular concern for individuals already at risk for age-related impairments in muscle mass and function, such as middle-aged and older adults. This session is important for filling current practice and knowledge gaps, providing clinicians with strategies to optimize patient outcomes in the context of GLP-1RA therapy. It is structured to be both informative and interactive, incorporating visuals, thought-provoking questions, and problem-solving exercises and to equip attendees with the tools and knowledge necessary to optimize GLP-1RA therapies in their daily clinical practice, ultimately leading to better patient outcomes.

CME/CE Expiration Date: 4/27/28

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.